We narrowed to 14,392 results for: RING

#140555-AAV9

Ready-to-use AAV9 particles produced from pAAV-hsyn-GRAB_DA-mut (#140555). In addition to the viral particles, you will also receive purified pAAV-hsyn-GRAB_DA-mut plasmid DNA. Synapsin-driven expression of control dopamine sensor GRAB_DA-mut (does not respond to DA). These AAV preparations are suitable purity for injection into animals.

Yulong Li

Sun et al Nat Methods. 2020 Nov;17(11):1156-1166.

Aug. 31, 2021

Academic Institutions and Nonprofits only

#140558-AAV9

Ready-to-use AAV9 particles produced from pAAV-hsyn-GRAB_rDA-mut (#140558). In addition to the viral particles, you will also receive purified pAAV-hsyn-GRAB_rDA-mut plasmid DNA. Synapsin-driven expression of control red fluorescent dopamine sensor GRAB_rDA-mut (does not respond to DA). These AAV preparations are suitable purity for injection into animals.

Yulong Li

Sun et al Nat Methods. 2020 Nov;17(11):1156-1166.

Aug. 31, 2021

Academic Institutions and Nonprofits only

#200778-AAV8

Ready-to-use AAV8 particles produced from AAV-∆Hapln1 (#200778). In addition to the viral particles, you will also receive purified AAV-∆Hapln1 plasmid DNA. Syn-driven, HAPLN1(delta40-154)-cfGFP expression. These AAV preparations are suitable purity for injection into animals.

Alexander Dityatev

Ramsaran et al Science. 2023 May 5;380(6644):543-551. d

Nov. 13, 2025

Academic Institutions and Nonprofits only

#200777-AAV8

Ready-to-use AAV8 particles produced from AAV-HAPLN1 (#200777). In addition to the viral particles, you will also receive purified AAV-HAPLN1 plasmid DNA. Syn-driven, HAPLN1-cfGFP expression. These AAV preparations are suitable purity for injection into animals.

Alexander Dityatev

Ramsaran et al Science. 2023 May 5;380(6644):543-551. d

Nov. 13, 2025

Academic Institutions and Nonprofits only

#200773-AAV8

Ready-to-use AAV8 particles produced from AAV-cfGFP (#200773). In addition to the viral particles, you will also receive purified AAV-cfGFP plasmid DNA. Syn-driven, cysteine-free GFP (cfGFP) expression. These AAV preparations are suitable purity for injection into animals.

Alexander Dityatev

Ramsaran et al Science. 2023 May 5;380(6644):543-551. d

Nov. 13, 2025

Academic Institutions and Nonprofits only

#208698-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn-GRAB-gDA3m (#208698). In addition to the viral particles, you will also receive purified pAAV-hSyn-GRAB-gDA3m plasmid DNA. Syn-driven expression of the genetically-encoded fluorescent dopamine (DA) sensor GRAB_gDA3m in neurons. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Zhuo et al Nat Methods. 2023 Nov 30. doi: 10.1038/s

Sept. 27, 2024

Academic Institutions and Nonprofits only

#121922-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn-GRAB_ACh3.0 (#121922). In addition to the viral particles, you will also receive purified pAAV-hSyn-GRAB_ACh3.0 plasmid DNA. Syn-driven expression of the genetically-encoded fluorescent acethycholine(ACh) sensor GRAB-ACh3.0. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Jing et al Nat Methods. 2020 Sep 28. pii: 10.1038/s

June 21, 2024

Academic Institutions and Nonprofits only

#131004-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn-GCaMP 6m-p2A-ChRmine-Kv2.1-WPRE (#131004). In addition to the viral particles, you will also receive purified pAAV-hSyn-GCaMP 6m-p2A-ChRmine-Kv2.1-WPRE plasmid DNA. hSyn-driven expression of calcium sensor GCaMP6m and bicistronic ChRmine (red-shifted channelrhodopsin). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

June 4, 2020

Academic Institutions and Nonprofits only

#105677-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV_hSyn1-SIO-stGtACR2-FusionRed (#105677). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR2-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

July 8, 2020

Academic Institutions and Nonprofits only

#105669-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-CKIIa-stGtACR2-FusionRed (#105669). In addition to the viral particles, you will also receive purified pAAV-CKIIa-stGtACR2-FusionRed plasmid DNA. CaMKIIa-driven, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

July 8, 2020

Academic Institutions and Nonprofits only

#179218

sgRNAs that target frequently occurring cancer associated mutations identified in the MSK IMPACT dataset that can be modeled with cytosine base editing.

Lukas Dow

Sanchez-Rivera et al Nat Biotechnol. 2022 Feb 14. pii: 10.103

June 16, 2022

Academic Institutions and Nonprofits only

#179217

sgRNAs that target frequently occurring cancer associated mutations identified in the MSK IMPACT dataset that can be modeled with cytosine base editing.

Lukas Dow

Sanchez-Rivera et al Nat Biotechnol. 2022 Feb 14. pii: 10.103

June 16, 2022

Academic Institutions and Nonprofits only